Process for producing and using secretomes derived from mesenchymal stem cells - Patent Application 20070122999
The MSC secretome composition addresses delivery challenges to ocular tissues by providing a balanced factor formulation for targeted therapy, enhancing wound healing and vision preservation in ocular conditions.
Patent Information
- Application Number
- JP2021560632
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-02-07
- Filing Date
- 2020-04-07
- Publication Date
- 2025-11-04
- Estimated Expiration
- 2040-04-07
AI Technical Summary
Current regenerative therapies for ocular conditions face challenges in delivering therapeutic payloads to hard-to-reach sensory cells, are susceptible to immune rejection, and lack effective treatments for cellular structures of the retina or anterior chamber, with existing topical eye drops having low efficacy due to anatomical constraints.
A mesenchymal stem cell (MSC) secretome composition is developed, comprising specific factors and formulations for targeted ocular delivery, including IDO activity control, balanced trophic factors, and anti-angiogenic properties, formulated for stability and safety, with methods for production and characterization.
The MSC secretome effectively targets and treats ocular injuries, promoting wound healing, reducing angiogenesis, and inhibiting scarring while maintaining vision, with improved delivery and stability.